NCT00625352 - Study of Developing an Optimal Gemcitabine Based Regimen to Treat Elderly Patients With Advanced Non-Small Cell Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

December 31, 2009

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Gemcitabine, UFT

Gemcitabine 1,250mg/m2 IV on D1 and D8 of every 3 weeks combined with UFT 400mg daily PO for 14 days every 3 weeks. Gemcitabine will be administered to patients a maximum of 4 cycles, and then discontinued. UFT will be continued until progression.

Trial Locations (1)

682-714

RECRUITING

Ulsan University Hospital, Ulsan